ArticleScientific reports2024
Artificial intelligence-based optimization for extracellular L-glutaminase free L-asparaginase production by Streptomyces violaceoruber under solid state fermentation conditions.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Unlocking the Bioactive Potential of Streptomyces: A Multidisciplinary Approach to Strain Improvement.MicrobiologyOpen · 2026Review
- Sustainable gold nanoparticles using Jania rubens, targeted therapeutic potential in prostate cancer and mechanistic insights via GO/KEGG pathway analysis.Scientific reports · 2026Article
- L‒asparaginase activity in some endophytic fungi: Glutaminase‒free and low urease co‒activities.PloS one · 2026Article
- Biofabrication, statistical optimization, and characterization of collagen nanoparticles synthesized via Streptomyces cell-free system for cancer therapy.Scientific reports · 2025Article
- L-asparaginase: a review of microbial production and protein engineering with translational applications for oncology and food safety.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterial L-asparaginase is a highly effective chemotherapeutic drug and a cornerstone of treatment protocols used for treatment the acute lymphoblastic leukemia in pediatric oncology. A potential actinomycete isolate, Streptomyces sp. strain NEAE-99, produces glutaminase-free L-asparaginase was isolated from a soil sample. This potential strain was identified as S. violaceoruber strain NEAE-99. The central composite design (CCD) approach was utilized for finding the optimal values for four variables including the mixture of soybean and wheat bran in a 1:1 ratio (w/w), the concentrations of dextrose, L-asparagine, and potassium nitrate under solid state fermentation conditions. Through the use of an artificial neural network (ANN), the production of L-asparaginase by S. violaceoruber has been investigated, validated, and predicted in comparison to CCD. It was found that the optimal predicted conditions for maximum L-asparaginase production (216.19 U/gds) were 8.46 g/250 mL Erlenmeyer flask of soybean and wheat bran mixture in a 1:1 ratio (w/w), 2.2 g/L of dextrose, 18.97 g/L of L-asparagine, and 1.34 g/L of KNO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.